SLC29A1 and cancer: Increasing doses of the hENT1-specific inhibitor S-(4-Nitrobenzyl)-6-thioinosine (NBMPR) dramatically decreased the intracellular levels of [3H]-gemcitabine in cancer cells (Figure 2C) and PSCs (Figure 2D).